A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria.
A total of 100 male Zambian patients with symptomatic falciparum malaria were treated with either two tablets of mefloquine plus sulfadoxine-pyrimethamine (Fansimef) or three tablets of sulfadoxine-pyrimethamine (Fansidar) as a single dose. The patients were kept under observation from day 0 (day of treatment) to day 28 and all were cured. An S-type of response was seen in all patients; one patient in the Fansimef group inexplicably remained positive for Plasmodium falciparum trophozoites until day 6. There were no cases of recrudescence.The rate of clearance of parasitaemia was similar in both groups. The rate of clearance of fever was marginally faster in the Fansimef group. Side-effects such as pruritus, diarrhoea and abdominal pain occurred after both drugs but were mild and transient; tolerance was slightly better with Fansimef. Severe orthostatic hypotension occurred in 20% of the Fansidar patients and in only 2% of the Fansimef patients; this was reversed by bed rest. Haematological and biochemical parameters were generally not modified in an undesirable manner by the administration of these drugs.
Ekue
J M
JM
Phiri
D E
DE
Sheth
U K
UK
Mukunyandela
M
M
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D015767:Mefloquine / Q000031:analogs & derivatives*; D008875:Middle Aged; D010963:Plasmodium falciparum; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D000962:Antimalarials; D004338:Drug Combinations; D015767:Mefloquine; D011739:Pyrimethamine; D011804:Quinolines; D013413:Sulfadoxine; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; C046846:mefloquine-sulfadoxine-pyrimethamine; D000096926:Benzenesulfonamides